Eric Warren Biography and Net Worth

Chief Commercial Officer of Mineralys Therapeutics

Eric Warren, R.Ph. joined Mineralys Therapeutics as Chief Commercial Officer in April 2025. Prior to joining us, Eric spent that last four years at Esperion Therapeutics where he most recently served as their Chief Commercial Officer.

In his ~30 years in the pharmaceutical industry, Eric has developed a breadth of clinical and commercial expertise, focusing primarily on cardio-metabolic and acute care medicine.

Eric started his career as a pharmacist, with experience in the community and hospital settings. He made the transition to industry in 1996, joining Merck & Co. Inc where he went on hold positions of increasing responsibility for almost two decades. Eric broadened his breadth of experience, with commercial roles at Genzyme, Pfizer, Sanofi and Nabriva.

Throughout his career he has always made it his mission to break down silos and ensure rapid patient adoption.

Eric holds a Bachelor of Science in Pharmacy and is a licensed pharmacist in New York State.

What is Eric Warren's net worth?: The estimated net worth of Eric Warren is at least $1.04 million as of June 26th, 2026. Mr. Warren owns 38,400 shares of Mineralys Therapeutics stock worth more than $1,036,032 as of July 1st. This net worth evaluation does not reflect any other assets that Mr. Warren may own. Learn More about Eric Warren's net worth.
How do I contact Eric Warren?: The corporate mailing address for Mr. Warren and other Mineralys Therapeutics executives is , , . Mineralys Therapeutics can also be reached via phone at 888-378-6240 and via email at [email protected]. Learn More on Eric Warren's contact information.
Has Eric Warren been buying or selling shares of Mineralys Therapeutics?: Eric Warren has not been actively trading shares of Mineralys Therapeutics over the course of the past ninety days. Most recently, Eric Warren sold 104,124 shares of the business's stock in a transaction on Friday, June 26th. The shares were sold at an average price of $25.90, for a transaction totalling $2,696,811.60. Following the completion of the sale, the insider now directly owns 38,400 shares of the company's stock, valued at $994,560. Learn More on Eric Warren's trading history.
Who are Mineralys Therapeutics' active insiders?: Mineralys Therapeutics' insider roster includes Srinivas Akkaraju (Director), Jon Congleton (CEO), Alexander Gold (Director), Daphne Karydas (Director), Adam Levy (Chief Financial Officer), David Rodman (Chief Medical Officer), Brian Slingsby (Director), and Eric Warren (Chief Commercial Officer). Learn More on Mineralys Therapeutics' active insiders.
Are insiders buying or selling shares of Mineralys Therapeutics?: In the last twelve months, Mineralys Therapeutics insiders bought shares 3 times. They purchased a total of 2,075,405 shares worth more than $52,354,246.50. In the last twelve months, insiders at the sold shares 52 times. They sold a total of 2,248,000 shares worth more than $85,135,331.23. The most recent insider tranaction occured on June, 30th when CEO Jon Congleton sold 75,000 shares worth more than $1,960,500.00. Insiders at Mineralys Therapeutics own 18.9% of the company. Learn More about insider trades at Mineralys Therapeutics.
Information on this page was last updated on 6/30/2026.

Eric Warren Insider Trading History at Mineralys Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/26/2026	Sell	104,124	$25.90	$2,696,811.60	38,400

Eric Warren Buying and Selling Activity at Mineralys Therapeutics

Mineralys Therapeutics Company Overview

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Today's Range

Now: $26.98

$25.56

$27.19

50 Day Range

MA: $27.19

$22.50

$31.54

2 Week Range

Now: $26.98

$12.59

$47.65

Volume

2,030,353 shs

Average Volume

2,295,579 shs

Market Capitalization

$2.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57